More recently, venetoclax resistance in monocytic AML has been attributed to a distinct monocytic LSC population (CD34−CD14−CD11b−CD36−), which is immunophenotypically distinct from previously described CD34− LSC subsets and characterized by reduced BCL2 dependence (Pei et al., 2023). Here, CD34 is linked to acute myeloid leukemia.